NASH-HCC tumors revealed TERT promoter (56%), CTNNB1 (28%), TP53 (18%) and Activin A Receptor Type 2A (ACVR2A) (10%) as the most frequently mutated genes. This evidence concerns the gene TP53 and hepatocellular carcinoma.